ABIO Market Cap History
Below is a table of the ABIO market cap history going back to 9/4/2015:

Date ABIO Market Cap
9/4/201557.80M
11/10/201547.70M
3/15/201633.51M
5/9/201632.09M
8/5/201627.65M
11/10/201620.89M
3/17/201723.74M
5/11/201722.18M
7/31/201721.74M
11/7/201714.10M
3/19/20189.04M
5/4/20187.10M
8/7/20189.61M
11/12/20189.89M
2/22/20198.44M
4/4/20195.72M
5/6/201912.50M
7/31/20199.97M
11/1/20198.16M
2/13/20208.74M
5/5/20206.04M
3/16/202160.67M
5/10/202144.10M
8/3/202143.52M
11/1/202138.91M
3/11/202230.41M
4/29/202234.15M
8/1/202234.73M
10/27/202230.12M

Also see: ABIO Shares Outstanding History
and ABIO YTD Return
ABIO Historical Market Cap:
-8.71% CAGR
ABIO Historical Market Cap: +-8.71% CAGR

Mouse over chart for data details
9/4/2015 ...10/27/2022
ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. We show 29 historical shares outstanding datapoints in our ABIO shares outstanding history coverage, used to compute ABIO market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing ABIO market cap history over the course of time is important for investors interested in comparing ABIO's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of ABIO versus a peer is one thing; comparing ABIO market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like ABIO can fluctuate over the course of history. With this page we aim to empower investors researching ABIO by allowing them to research the ABIO market cap history.
Quotes delayed 20 minutes

Email EnvelopeFree ABIO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
ARCA biopharma (ABIO) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

ABMD Market Cap History
ABOS Market Cap History
ABSI Market Cap History
ABT Market Cap History
ABVC Market Cap History
ACAD Market Cap History
ACCD Market Cap History
ACER Market Cap History
ACET Market Cap History
ACHC Market Cap History
More Healthcare companies »

 

ABIO Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.